Summary:
This study will evaluate the efficacy, safety, and tolerability of rapastinel in patients with major depressive disorder. the study will take up to 3 weeks.
Qualified Participants Must:
• Be between 18 and 65 years of age (Adult)
•
Have current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1
•
Be diagnosed with depression
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.